These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35513765)

  • 1. Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes.
    Matza LS; Stewart KD; Landó LF; Patel H; Boye KS
    Patient; 2022 May; 15(3):367-377. PubMed ID: 35513765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
    Nauck MA; D'Alessio DA
    Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.
    Tall Bull S; Nuffer W; Trujillo JM
    J Diabetes Complications; 2022 Dec; 36(12):108332. PubMed ID: 36375235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
    Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
    Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
    Thomas MK; Nikooienejad A; Bray R; Cui X; Wilson J; Duffin K; Milicevic Z; Haupt A; Robins DA
    J Clin Endocrinol Metab; 2021 Jan; 106(2):388-396. PubMed ID: 33236115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.
    Lingvay I; Mosenzon O; Brown K; Cui X; O'Neill C; Fernández Landó L; Patel H
    Cardiovasc Diabetol; 2023 Mar; 22(1):66. PubMed ID: 36964557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.
    Wong E; Cope R; Dima L; Nguyen T
    Am J Ther; 2023 Jan-Feb 01; 30(1):e26-e35. PubMed ID: 36516422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.
    Nowak M; Nowak W; Grzeszczak W
    Endokrynol Pol; 2022; 73(4):745-755. PubMed ID: 35593668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
    Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
    Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.
    Min T; Bain SC
    Diabetes Ther; 2021 Jan; 12(1):143-157. PubMed ID: 33325008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program.
    Frías JP
    Expert Rev Endocrinol Metab; 2023 Mar; 18(2):111-130. PubMed ID: 36908082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight loss efficiency and safety of tirzepatide: A Systematic review.
    Lin F; Yu B; Ling B; Lv G; Shang H; Zhao X; Jie X; Chen J; Li Y
    PLoS One; 2023; 18(5):e0285197. PubMed ID: 37141329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
    Meng Z; Yang M; Wen H; Zhou S; Xiong C; Wang Y
    Front Endocrinol (Lausanne); 2023; 14():1121387. PubMed ID: 37051199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.
    Zhang X; McAdam Marx C
    J Manag Care Spec Pharm; 2023 Mar; 29(3):276-284. PubMed ID: 36840958
    [No Abstract]   [Full Text] [Related]  

  • 18. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.
    Valentine WJ; Hoog M; Mody R; Belger M; Pollock R
    Diabetes Obes Metab; 2023 May; 25(5):1292-1300. PubMed ID: 36655340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Drug: Tirzepatide (Mounjaro
    Gettman L
    Sr Care Pharm; 2023 Feb; 38(2):50-62. PubMed ID: 36751934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.